Does the media prefer ZNTL or BTMD?

In the previous week, biote had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for biote and 1 mentions for Zentalis Pharmaceuticals. biote's average media sentiment score of 0.23 beat Zentalis Pharmaceuticals' score of 0.00 indicating that biote is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral biote 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, ORGO or BTMD?

Organogenesis has higher revenue and earnings than biote. Organogenesis is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organogenesis $564.17M 0.54 $37.03M -$0.19 N/A biote $192.22M 0.44 $27.05M $0.44 5.17

Is ORGO or BTMD more profitable?

biote has a net margin of 8.29% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets Organogenesis -0.84% 9.63% 4.76% biote 8.29% -25.72% 15.12%

Does the media favor ORGO or BTMD?

In the previous week, biote had 2 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for biote and 1 mentions for Organogenesis. biote's average media sentiment score of 0.23 beat Organogenesis' score of 0.00 indicating that biote is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral biote 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NLTX or BTMD?

biote has a consensus price target of $2.75, suggesting a potential upside of 20.88%. Given biote's stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation & earnings, LYEL or BTMD?

biote has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lyell Immunopharma $40K 8,348.38 -$274.45M -$13.80 N/A biote $192.22M 0.44 $27.05M $0.44 5.17

Is LYEL or BTMD more profitable?

biote has a net margin of 8.29% compared to Lyell Immunopharma's net margin of -794,858.12%. biote's return on equity of -25.72% beat Lyell Immunopharma's return on equity. Company Net Margins Return on Equity Return on Assets Lyell Immunopharma -794,858.12% -85.71% -66.41% biote 8.29% -25.72% 15.12%

Does the media favor LYEL or BTMD?

In the previous week, biote had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for biote and 1 mentions for Lyell Immunopharma. biote's average media sentiment score of 0.23 beat Lyell Immunopharma's score of 0.00 indicating that biote is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral biote 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, SNDL or BTMD?

biote has lower revenue, but higher earnings than SNDL. SNDL is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SNDL $677.32M 0.46 -$11.29M -$0.06 N/A biote $192.22M 0.44 $27.05M $0.44 5.17

Is SNDL or BTMD more profitable?

biote has a net margin of 8.29% compared to SNDL's net margin of -2.36%. SNDL's return on equity of -2.01% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets SNDL -2.36% -2.01% -1.67% biote 8.29% -25.72% 15.12%

Does the media refer more to SNDL or BTMD?

In the previous week, SNDL had 8 more articles in the media than biote. MarketBeat recorded 11 mentions for SNDL and 3 mentions for biote. biote's average media sentiment score of 0.23 beat SNDL's score of 0.01 indicating that biote is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SNDL 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral biote 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Live Earnings Conference Call: biote will host a live Q2 2026 earnings call on August 5, 2026 at 5:00PM ET. Get details.

biote (BTMD) Competitors

$2.28 -0.02 (-0.66%)

Closing price 08/4/2026 03:59 PM Eastern

Extended Trading

$2.27 0.00 (-0.13%)

As of 07:00 AM Eastern

Compare

BTMD vs. ZNTL, ORGO, NLTX, LYEL, and SNDL

Should you buy biote stock or one of its competitors? MarketBeat compares biote with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with biote include Zentalis Pharmaceuticals (ZNTL), Organogenesis (ORGO), Neoleukin Therapeutics (NLTX), Lyell Immunopharma (LYEL), and SNDL (SNDL).

How does biote compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Zentalis Pharmaceuticals currently has a consensus price target of $6.75, suggesting a potential upside of 38.32%. biote has a consensus price target of $2.75, suggesting a potential upside of 20.88%. Given Zentalis Pharmaceuticals' higher possible upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, biote had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for biote and 1 mentions for Zentalis Pharmaceuticals. biote's average media sentiment score of 0.23 beat Zentalis Pharmaceuticals' score of 0.00 indicating that biote is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
biote	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.7% of biote shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

biote has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	5.15	-$137.06M	-$1.73	N/A
biote	$192.22M	0.44	$27.05M	$0.44	5.17

biote has a net margin of 8.29% compared to Zentalis Pharmaceuticals' net margin of 0.00%. biote's return on equity of -25.72% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
biote	8.29%	-25.72%	15.12%

Zentalis Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, biote has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

Summary

biote beats Zentalis Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does biote compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

biote has a net margin of 8.29% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
biote	8.29%	-25.72%	15.12%

Organogenesis currently has a consensus price target of $5.75, suggesting a potential upside of 142.62%. biote has a consensus price target of $2.75, suggesting a potential upside of 20.88%. Given Organogenesis' higher possible upside, equities analysts plainly believe Organogenesis is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Organogenesis has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, biote has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

In the previous week, biote had 2 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for biote and 1 mentions for Organogenesis. biote's average media sentiment score of 0.23 beat Organogenesis' score of 0.00 indicating that biote is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
biote	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organogenesis has higher revenue and earnings than biote. Organogenesis is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.54	$37.03M	-$0.19	N/A
biote	$192.22M	0.44	$27.05M	$0.44	5.17

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 18.8% of Organogenesis shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

biote beats Organogenesis on 10 of the 16 factors compared between the two stocks.

How does biote compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, biote has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

In the previous week, biote had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for biote and 0 mentions for Neoleukin Therapeutics. biote's average media sentiment score of 0.23 beat Neoleukin Therapeutics' score of 0.00 indicating that biote is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
biote	Neutral

biote has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
biote	$192.22M	0.44	$27.05M	$0.44	5.17

biote has a net margin of 8.29% compared to Neoleukin Therapeutics' net margin of 0.00%. biote's return on equity of -25.72% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
biote	8.29%	-25.72%	15.12%

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

biote has a consensus price target of $2.75, suggesting a potential upside of 20.88%. Given biote's stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

biote beats Neoleukin Therapeutics on 15 of the 16 factors compared between the two stocks.

How does biote compare to Lyell Immunopharma?

Lyell Immunopharma (NASDAQ:LYEL) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Lyell Immunopharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, biote has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

biote has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	8,348.38	-$274.45M	-$13.80	N/A
biote	$192.22M	0.44	$27.05M	$0.44	5.17

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, biote had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for biote and 1 mentions for Lyell Immunopharma. biote's average media sentiment score of 0.23 beat Lyell Immunopharma's score of 0.00 indicating that biote is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
biote	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lyell Immunopharma presently has a consensus price target of $43.20, suggesting a potential upside of 216.95%. biote has a consensus price target of $2.75, suggesting a potential upside of 20.88%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Lyell Immunopharma is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

biote has a net margin of 8.29% compared to Lyell Immunopharma's net margin of -794,858.12%. biote's return on equity of -25.72% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
biote	8.29%	-25.72%	15.12%

Summary

biote beats Lyell Immunopharma on 11 of the 16 factors compared between the two stocks.

How does biote compare to SNDL?

SNDL (NASDAQ:SNDL) and biote (NASDAQ:BTMD) are related small-cap companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

SNDL has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, biote has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

SNDL presently has a consensus target price of $5.00, indicating a potential upside of 313.22%. biote has a consensus target price of $2.75, indicating a potential upside of 20.88%. Given SNDL's higher possible upside, equities research analysts clearly believe SNDL is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

21.7% of biote shares are held by institutional investors. 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, SNDL had 8 more articles in the media than biote. MarketBeat recorded 11 mentions for SNDL and 3 mentions for biote. biote's average media sentiment score of 0.23 beat SNDL's score of 0.01 indicating that biote is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SNDL	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
biote	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

biote has lower revenue, but higher earnings than SNDL. SNDL is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SNDL	$677.32M	0.46	-$11.29M	-$0.06	N/A
biote	$192.22M	0.44	$27.05M	$0.44	5.17

biote has a net margin of 8.29% compared to SNDL's net margin of -2.36%. SNDL's return on equity of -2.01% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SNDL	-2.36%	-2.01%	-1.67%
biote	8.29%	-25.72%	15.12%

Summary

biote beats SNDL on 11 of the 16 factors compared between the two stocks.

Get biote News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTMD vs. The Competition

Export

Metric	biote	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$86.06M	$9.95B	$6.83B	$12.77B
Dividend Yield	N/A	2.55%	2.60%	10.01%
P/E Ratio	5.17	25.62	279.15	25.53
Price / Sales	0.44	4.81	587.36	92.31
Price / Cash	3.94	126.64	72.11	49.39
Price / Book	-1.63	5.16	13.06	6.11
Net Income	$27.05M	$312.25M	$3.48B	$347.58M
7 Day Performance	11.52%	0.97%	3.38%	4.91%
1 Month Performance	4.84%	-0.85%	-2.81%	-2.06%
1 Year Performance	-45.44%	24.53%	73.07%	21.03%

biote Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTMD biote	4.0115 of 5 stars	$2.28 -0.7%	$2.75 +20.9%	-44.9%	$86.06M	$192.22M	5.17	194	News Coverage
ZNTL Zentalis Pharmaceuticals	1.7364 of 5 stars	$4.62 +2.4%	$6.75 +46.1%	+251.1%	$328.88M	N/A	N/A	160
ORGO Organogenesis	1.3992 of 5 stars	$2.53 -0.8%	$5.75 +127.3%	-48.5%	$325.55M	$512.59M	N/A	950	Upcoming Earnings
NLTX Neoleukin Therapeutics	N/A	$34.62 -0.8%	N/A	+50.9%	$325.36M	N/A	N/A	90	High Trading Volume
LYEL Lyell Immunopharma	2.6045 of 5 stars	$12.99 +0.2%	$43.20 +232.6%	+19.9%	$318.31M	$31K	N/A	270	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTMD) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

biote (BTMD) Competitors

BTMD vs. ZNTL, ORGO, NLTX, LYEL, and SNDL

How does biote compare to Zentalis Pharmaceuticals?

Summary

How does biote compare to Organogenesis?

Summary

How does biote compare to Neoleukin Therapeutics?

Summary

How does biote compare to Lyell Immunopharma?

Summary

How does biote compare to SNDL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD vs. The Competition

biote Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

biote (BTMD) Competitors

BTMD vs. ZNTL, ORGO, NLTX, LYEL, and SNDL

How does biote compare to Zentalis Pharmaceuticals?

Do analysts recommend ZNTL or BTMD?

Does the media prefer ZNTL or BTMD?

Do institutionals and insiders hold more shares of ZNTL or BTMD?

Which has preferable valuation & earnings, ZNTL or BTMD?

Is ZNTL or BTMD more profitable?

Which has more volatility and risk, ZNTL or BTMD?

Summary

How does biote compare to Organogenesis?

Is ORGO or BTMD more profitable?

Do analysts recommend ORGO or BTMD?

Which has more volatility & risk, ORGO or BTMD?

Does the media favor ORGO or BTMD?

Which has better valuation and earnings, ORGO or BTMD?

Do insiders & institutionals hold more shares of ORGO or BTMD?

Summary

How does biote compare to Neoleukin Therapeutics?

Which has more risk and volatility, NLTX or BTMD?

Does the media prefer NLTX or BTMD?

Which has higher valuation and earnings, NLTX or BTMD?

Is NLTX or BTMD more profitable?

Do institutionals & insiders have more ownership in NLTX or BTMD?

Do analysts rate NLTX or BTMD?

Summary

How does biote compare to Lyell Immunopharma?

Which has more volatility & risk, LYEL or BTMD?

Which has better valuation & earnings, LYEL or BTMD?

Do insiders and institutionals have more ownership in LYEL or BTMD?

Does the media favor LYEL or BTMD?

Do analysts rate LYEL or BTMD?

Is LYEL or BTMD more profitable?

Summary

How does biote compare to SNDL?

Which has more volatility and risk, SNDL or BTMD?

Do analysts recommend SNDL or BTMD?

Do insiders & institutionals have more ownership in SNDL or BTMD?

Does the media refer more to SNDL or BTMD?

Which has stronger earnings and valuation, SNDL or BTMD?

Is SNDL or BTMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD vs. The Competition

biote Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools